



## Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection

Harry Sokol, Sarah Jegou, Claire Mcquitty, Marjolene Straub, Valentin Leducq, Cecilia Landman, Julien Kirchgesner, Guillaume Le Gall, Anne Bourrier, Isabelle Nion-Larmurier, et al.

### ► To cite this version:

Harry Sokol, Sarah Jegou, Claire Mcquitty, Marjolene Straub, Valentin Leducq, et al.. Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. *Gut microbes*, 2017, 9 (1), pp.1-6. 10.1080/19490976.2017.1361092 . hal-01582584

HAL Id: hal-01582584

<https://hal.sorbonne-universite.fr/hal-01582584>

Submitted on 6 Sep 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Specificities of the intestinal microbiota in patients with inflammatory bowel disease and *Clostridium difficile* infection

3

4 Harry Sokol<sup>1,2,3,4\*</sup>, Sarah Jegou<sup>1,4</sup>, Claire McQuitty<sup>1,4</sup>, Marjolene Straub<sup>1,4</sup>, Valentin Leducq<sup>1,4</sup>,  
5 Cecilia Landman<sup>3,4</sup>, Julien Kirchgesner<sup>3,4</sup>, Guillaume Le Gall<sup>3,4</sup>, Anne Bourrier<sup>3,4</sup>, Isabelle Nion-  
6 Larmurier<sup>3,4</sup>, Jacques Cosnes<sup>3,4</sup>, Philippe Seksik<sup>3,4</sup>, Mathias L. Richard<sup>2,4</sup> and Laurent  
7 Beaugerie<sup>3,4</sup>

8

<sup>9</sup> <sup>1</sup> Sorbonne University - UPMC Univ Paris 06, INSERM ERL 1157, Avenir Team Gut Microbiota  
<sup>10</sup> and Immunity, UMR 7203, Saint-Antoine Hospital, Paris, France

<sup>11</sup> <sup>2</sup>INRA, UMR1319 Micalis & AgroParisTech, Jouy en Josas, France

12     <sup>3</sup> Department of Gastroenterology, Saint Antoine Hospital, AP-HP, UPMC Univ Paris 06, Paris,  
13     France

14 <sup>4</sup>Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France

15

16 \*Corresponding author: Harry Sokol, Service de Gastroentérologie et Nutrition, Hôpital Saint-  
17 Antoine, 184 rue du faubourg St Antoine, 75571 Paris cedex 12, France. E-  
18 mail: [harry.sokol@aphp.fr](mailto:harry.sokol@aphp.fr) Phone: +33 149 283 162. Fax: +33 149 283 188

19

## 20 Short title: Microbiota in IBD with CDI

21

22 Abbreviations: inflammatory bowel diseases (IBD), healthy subjects (HS), Crohn's disease (CD),  
23 ulcerative colitis (UC)

24

25    **Abstract**

26    **Background and Aims:** *Clostridium difficile* infection (CDI) is a common complication in  
27    inflammatory bowel disease (IBD) and has been associated with poor IBD outcome. Intestinal  
28    microbiota composition in IBD patients with CDI has not been specifically evaluated to date.

29    **Methods:** The fecal microbiota of 56 IBD patients, including 8 in flare with concomitant CDI,  
30    24 in flare without CDI, and 24 in remission, as well as 24 healthy subjects, was studied using  
31    16S sequencing. Analysis was performed using the Qiime pipeline.

32    **Results:** Compared to IBD patients without CDI, IBD patients with CDI had more pronounced  
33    dysbiosis with higher levels of *Ruminococcus gnavus* and *Enterococcus* operational taxonomic  
34    units (OTUs) and lower levels of *Blautia* and *Dorea* OTUs. Correlation network analysis  
35    suggested a disrupted ecosystem in IBD patients in flare, particularly in those with CDI.

36    **Conclusions:** In patients with IBD, CDI is associated with a more pronounced intestinal  
37    dysbiosis with specific alterations in intestinal microorganisms.

38

39    **Keywords:** IBD, *Clostridium difficile*

40

41 **Introduction**

42 *Clostridium difficile* infection (CDI) is a common complication of inflammatory bowel disease  
43 (IBD) and has been associated with a poor IBD outcome<sup>1</sup>. CDI typically occurs after a transient  
44 microbiota perturbation in the gut. Thus, antibiotic intake is a major risk factor in the general  
45 population. In IBD, as the gut microbiota is basally perturbed (i.e., dysbiosis)<sup>2</sup>, CDI can occur  
46 even without an antibiotic trigger.

47 Microbiota composition in patients with CDI is imbalanced and characterized by decreased  
48 biodiversity<sup>3,4</sup>, as well as notable increases and decreases in several taxa that are known to be  
49 increased and decreased in IBD<sup>4</sup>, respectively. For example, *Bifidobacterium* and members of  
50 Clostridium clusters IV and XIVa (such as *Faecalibacterium prausnitzii* or *Roseburia intestinalis*)  
51 were decreased, while Enterobacteriaceae and *Enterococcus* were increased<sup>5</sup>. However,  
52 intestinal microbiota composition in IBD patients with CDI has not been specifically evaluated  
53 to date.

54

55 **Results**

56 **Population, microbiota composition and diversity**

57 Our study population was composed of 56 IBD patients, including 8 in flare with concomitant  
58 CDI, 24 in flare without CDI, and 24 patients in remission, as well as 24 healthy subjects (HS)  
59 (Table 1). IBD patients in flare without CDI and patients in remission were matched to patients  
60 in flare with CDI (3:1) based on IBD subtype and topography. None of the study participants  
61 reported having taken antibiotics or using colon-cleansing products for at least 2 months prior  
62 to enrollment.

63 Beta diversity analysis showed a clustering of samples by disease phenotype and a progressive  
64 microbiota shift from HS to IBD in remission, to IBD in flare and finally to IBD in flare with CDI  
65 (Figure 1A-B). Compared with the HS samples, the alpha diversity (assessed by four different  
66 indexes) was significantly decreased in IBD patients, particularly in samples from patients in  
67 flare (Figure 1C, Suppl Figure 1A-B). There was no significant difference between patients with  
68 and without CDI.

69 As expected, most of the bacteria from both the IBD and HS samples belonged to the phyla  
70 Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria (Figure 1D), and the distribution  
71 of these phyla in the patients was in agreement with published data<sup>6</sup>. Firmicutes and  
72 Bacteroidetes were the most abundant in HS. In IBD patients, particularly those in flare, there  
73 was a decrease in Firmicutes (mostly from the Ruminococcaceae family) associated with an  
74 increase of Proteobacteria (mostly from the Enterobacteriaceae family ; Figure 1D, Suppl  
75 Figure 1C).

76

77 **Differential bacterial composition and altered microbial network in CDI**

78 To identify more precisely the impact of CDI on IBD microbiota, we directly compared the  
79 bacterial composition of IBD patients in flare, both with and without CDI, using LEfSe (Linear  
80 discriminant analysis Effect Size)<sup>7</sup>. We identified several OTU that differentiated patients with  
81 and without CDI (Figure 1E, Suppl Table 1). Several *Blautia* and *Dorea* OTUs were decreased  
82 in patients with CDI, whereas several *Clostridium*, *Ruminococcus gnavus* and *Enterococcus*  
83 OTUs were increased in patients with CDI.

84 To evaluate globally the microbial gut ecosystem and its alterations in IBD and CDI, we built a  
85 microbial correlation network by phenotype (Figure 2). In HS, we observed a highly connected  
86 network between many bacterial OTUs, suggesting the presence of a balanced and  
87 cooperative ecosystem. Although smaller than that of HS, the correlation network was also  
88 well-connected in IBD patients in remission. In contrast, the correlation network was  
89 disrupted in IBD patients in flare, with separated bacterial clusters being detected. For IBD  
90 patients in flare who also had CDI, the alterations were even more pronounced with a lower  
91 relative connectedness (2.1 vs 5.4 in IBD patients in flare without CDI,  $p<10^{-8}$ ) and no  
92 interaction between several groups of bacteria, suggesting a loss of cooperation in the  
93 ecosystem.

94

## 95 **Discussion**

96 To the best of our knowledge, this report presents the first detailed analysis of the intestinal  
97 microbiota of IBD patients both with and without CDI. In accordance with previous studies,  
98 we confirmed that the intestinal microbiota of IBD patients is dysbiotic. The current study  
99 showed that CDI in patients with IBD flare is associated with a more severe dysbiosis than in  
100 an IBD flare without CDI. This infection is characterized by specific alterations in intestinal  
101 microorganisms with an impaired microbial ecosystem. Interestingly, among the decreased  
102 bacterial OTUs in patients with CDI, we identified many genera known to be deficient in IBD  
103 compared to HS, such as *Blautia* and *Dorea*<sup>6</sup>. In addition, the *Ruminococcus gnavus* and  
104 *Enterococcus* OTUs that were increased in the patients with CDI have also been shown to be  
105 overrepresented in IBD patients compared to HS<sup>8,9</sup>. This finding indicates a deeper dysbiosis

106 in IBD patients with CDI. Moreover, several CDI features in non-IBD patients, such as increased  
107 numbers of *Enterococcus*<sup>5</sup>, were also found in the IBD patients.

108 In conclusion, this study showed that in patients with IBD, CDI is associated with a more  
109 pronounced intestinal dysbiosis. Whether this feature is a cause or a consequence of CDI is  
110 not established. Therefore, the next step will be to investigate microbiota factors associated  
111 with the risk of developing CDI in IBD as a prerequisite for preventive intervention.

112

## 113 **Materials and Methods**

### 114 **Patients and sample collection**

115 All patients were recruited at the Gastroenterology Department of the Saint Antoine Hospital  
116 (Paris, France) and provided informed consent. Approval was obtained from the local ethics  
117 committee (Comite de Protection des Personnes Ile-de-France IV, Suivitheque study). A  
118 diagnosis of IBD was defined by clinical, radiological, endoscopic and histological criteria. A  
119 flare was determined by the physician in charge of the patient based on clinical and biological  
120 data. None of the study participants reported having taken antibiotics or using colon-cleansing  
121 products for at least 2 months prior to enrollment. Patient characteristics are presented in  
122 Table 1. Samples from healthy subjects (HS) and from IBD patients without a *Clostridium*  
123 *difficile* infection were described previously<sup>2</sup>. Whole stools were collected in sterile boxes and  
124 immediately homogenized, and 0.2 g aliquots were frozen at -80°C for further analysis.

125

### 126 **Fecal DNA extraction**

127 Genomic DNA was extracted from 200 mg of feces as previously described<sup>1</sup>. Following  
128 microbial lysis with both mechanical and chemical steps, nucleic acids were precipitated in  
129 isopropanol for 10 minutes at room temperature, incubated for 15 minutes on ice and  
130 centrifuged for 30 minutes at 15,000 g and 4°C. Pellets were suspended in 112 µL of phosphate  
131 buffer and 12 µL of potassium acetate. After RNase treatment and DNA precipitation, nucleic  
132 acids were recovered via centrifugation at 15,000 g and 4°C for 30 minutes. The DNA pellet  
133 was suspended in 100 µL of TE buffer.

134

135 **16S rRNA gene sequencing**

136 After extraction, total DNA concentration was measured using PicoGreen (Invitrogen), and  
137 global 16S gene DNA copy numbers were measured using a qPCR method adapted from  
138 Maeda *et al.*<sup>10</sup>, enabling inhibition effect estimation and DNA concentration adjustment. The  
139 sequence region of the 16S rRNA gene spanning the variable region V3-V5 was amplified using  
140 the broad-range forward primer, For16S\_519 (CAGCMGCCGCGGTAAATAC), and reverse primer,  
141 Rev16S\_926 (CCGTCAATTCTTGTAGTTT). The amplification reaction (initial activation step at  
142 94°C for 1 min, followed by 30 cycles of 94°C for 15 s, 43°C for 15 s, 68°C for 45 s and a final  
143 incubation step at 68°C for 1 min) was performed in a total volume of 100 µL containing 1X  
144 PCR buffer, 2 mM MgSO<sub>4</sub>, 1 U of DNA High Fidelity Taq Polymerase (Invitrogen, Carlsbad, CA),  
145 625 nM of each barcoded primer (IDT), 250 µM of each dNTP (Invitrogen) and the  
146 concentration-adjusted DNA sample. A bidirectional library was prepared using the One  
147 Touch2 Template Kit and sequenced on PGM Ion Torrent using the Ion PGM Sequencing 400  
148 Kit (Life Technologies, Carlsbad, CA).

149

150 **16S rRNA gene sequence analysis**

151 The sequences were demultiplexed and quality filtered using the Quantitative Insights Into  
152 Microbial Ecology (QIIME, version 1.8.0) software package<sup>11</sup>. The sequences were trimmed for  
153 barcodes and PCR primers and were binned for a minimal sequence length of 200 bp. The  
154 sequences were then assigned to (OTUs) using the UCLUST algorithm<sup>12</sup> with a 97% threshold  
155 pairwise identity and taxonomically classified using the Greengenes reference database<sup>13</sup>.  
156 Rarefaction was performed (10,000 sequences per sample) and used to compare OTU  
157 abundances across samples. Principal component analyses (PCA) of the Bray Curtis distance,  
158 with each sample colored according to disease phenotype, were built and used to assess the  
159 variation between experimental groups. The number of observed species, as well as the  
160 Shannon, Simpson and Chao1 diversity indexes, were calculated using rarefied data (depth =  
161 10,000 sequences/sample) and used to characterize species diversity in a community.

162

163 **Clostridium difficile testing**

164 Diagnosis of CDI was performed using a stool culture on selective medium (TCCA, taurocholate  
165 cycloserine cefoxitine medium) and a stool cytotoxicity assay on MRC-5 cells. In cases in which  
166 a positive culture and negative stool cytotoxicity assay were obtained, a toxigenic culture  
167 (determination of the isolate's ability to produce toxins in vitro) was performed.

168

169 **Statistical analysis**

170 GraphPad Prism version 6.0 (San Diego, CA) was used for all analyses and graph preparation.  
171 For all graphical data, the results are expressed as the mean  $\pm$  SEM, and statistical analyses  
172 were performed using the 2-tailed nonparametric Mann–Whitney *U*-test or the Kruskal-Wallis  
173 test with Dunn's multiple comparison test. Statistical significance of the sample grouping for

174 the beta diversity analysis was performed using the Permanova method (9999 permutations).  
175 Differences with a P value less than 0.05 were considered to be significant.  
176 Comparisons between IBD patients with and without CDI was performed using the linear  
177 discriminant analysis (LDA) effect size (LEfSe) pipeline <sup>7</sup>.  
178 A correlation network was built using an OTU table and the Spearman correlation. Only OTUs  
179 present in >50% of the samples were used. The p values were corrected using the Benjamini  
180 and Hochberg procedure to control for the false discovery rate (FDR). Correlation network  
181 figures were built using Cytoscape 3.1.1. The relative connectedness of the networks was  
182 calculated by dividing the number of significant interactions (edges) by the number of taxa  
183 (nodes) in the network. Statistical significance was assessed by a chi-square test.

184

## 185 **Authors' Contributions**

186 HS designed and supervised the study. VL, SJ and CM provided technical help. HS, CL, JK, GL,  
187 AB, INL, JC, PS, LB, recruited the patients, HS performed the analysis and interpreted the  
188 data. HS wrote the manuscript.

189 The authors state that the manuscript, including related data, figures and tables, has not  
190 been previously published and that the manuscript is not under consideration elsewhere.

191

## 192 **Funding**

193 This study was supported by an unrestricted Biocodex grant.

194

195

196 **Conflicts of interest**

197 The authors disclose no conflicts of interest.

198

199 **References**

200 1. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease  
201 outcomes related to Clostridium difficile infection in patients with inflammatory bowel  
202 disease. Inflamm Bowel Dis. 2011 Apr;17(4):976-83. doi: 10.1002/ibd.21457.

203 2. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier  
204 A, Nion-Larmurier I et al. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048.  
205 doi: 10.1136/gutjnl-2015-310746.

206 3. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper  
207 EJ, Bartelsman JF, Tijssen JG et al. Duodenal infusion of donor feces for recurrent Clostridium  
208 difficile. N Engl JMed. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037.

209 4. Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, TurroniF, Duranti S,  
210 Mangifesta M, Viappiani A et al. Gut microbiota composition and Clostridium difficile infection  
211 in hospitalized elderly individuals: a metagenomic study. Sci Rep. 2016 May 11;6:25945. doi:  
212 10.1038/srep25945.

213 5. Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest.2014  
214 Oct;124(10):4182-9. doi: 10.1172/JCI72336.

- 215 6: Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko  
216 N, Snapper SB et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease  
217 and treatment. *Genome Biol.* 2012 Apr 16;13(9):R79. doi: 10.1186/gb-2012-13-9-r79.
- 218 7. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C.  
219 Metagenomic biomarker discovery and explanation. *Genome Biol.* 2011 Jun 24;12(6):R60. doi:  
220 10.1186/gb-2011-12-6-r60.
- 221 8. Hoffmann TW, Pham HP, Bridonneau C, Aubry C, Lamas B, Martin-Gallausiaux C, Moroldo  
222 M, Rainteau D, Lapaque N, Six A et al. Microorganisms linked to inflammatory bowel disease-  
223 associated dysbiosis differentially impact host physiology in gnotobiotic mice. *ISME J.* 2016  
224 Feb;10(2):460-77. doi: 10.1038/ismej.2015.127.
- 225 9. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, JärnerotG, Tysk C,  
226 Jansson JK, Engstrand L. A pyrosequencing study in twins shows that gastrointestinal  
227 microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology.*  
228 2010 Dec;139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049.
- 229 10. Maeda H, Fujimoto C, Haruki Y, Maeda T, Kokeguchi S, Petelin M, Arai H, Tanimoto I,  
230 Nishimura F, and Takashiba S. Quantitative real-time PCR using TaqMan and SYBR Green for  
231 *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*,  
232 *tetQ* gene and total bacteria. *FEMS Immunol Med Microbiol.* 2003; 39: 81-86.
- 233
- 234 11. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N,  
235 Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone  
236 CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA,

237 Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput  
238 community sequencing data. *Nat Methods*. 2010 May;7(5):335-6. doi: 10.1038/nmeth.f.303.

239 12. Edgar R.C. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*.  
240 2010; 26: 2460-2461. doi: 10.1093/bioinformatics/btq461.

241 13. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL,  
242 Knight R, and Hugenholtz P. An improved Greengenes taxonomy with explicit ranks for  
243 ecological and evolutionary analyses of bacteria and archaea. *ISME J*. 2012; 6: 610-618. doi:  
244 10.1038/ismej.2011.139.

245

246

247

248 **Figure Legends**

249 **Figure 1: Bacterial microbiota biodiversity and composition.** (A) Beta diversity. Principal  
250 coordinate analysis of the Bray Curtis distance with each sample colored by the disease  
251 phenotype. PC1, PC2, and PC3 represent the top three principal coordinates that captured the  
252 most diversity, with the fraction of diversity captured by that coordinate shown as a  
253 percentage. (B) PC1 value according disease phenotype (t test, \*\* = p< 0.01; \*\*\* = p< 0.001).  
254 (C) OTU number describing the diversity of the bacterial microbiota in the different groups  
255 studied (t test, \* = p< 0.05; \*\* = p< 0.01; \*\*\* = p< 0.001). (D) Global composition of bacteria at  
256 the phyla level. HS and patient sub-groups are labeled on the X-axis and expressed as the  
257 relative OTU abundance per group. (E) Bacterial taxa differentially enriched in IBD patients in  
258 flare both with and without CDI (generated using LeFSE analysis, LDA score >2).

259 **Figure 2: Bacterial microbiota correlation network.** Correlation network for the HS, IBD in  
260 remission, and IBD in flare both without and with CDI was generated using Cytoscape. Each  
261 circle (node) represents an OTU, the color represents its bacterial phylum (blue: Firmicutes;  
262 green: Bacteroidetes; orange: Proteobacteria), and its size represents the number of direct  
263 edges that it has. The edge color indicates the magnitude of the distance correlation; green  
264 indicates a positive correlation and red indicates a negative correlation (determined using the  
265 Spearman test). Statistical significance was determined for all pairwise comparisons; only  
266 significant correlations (p value < 0.05 after FDR correction) are displayed.

267

268

269

270

## **Supplementary Materials and Methods**

271






272




274 **Supplementary Figure Legend**


275 **Supplementary Figure 1: Bacterial microbiota biodiversity and composition.** (A) Chao1  
276 diversity index of the bacterial microbiota in the different groups studied. (B) Shannon  
277 diversity index of the bacterial microbiota in the different groups studied (t test, \* = p< 0.05;  
278 \*\* = p< 0.01; \*\*\* = p< 0.001). (C) Global composition of bacteria at the family level. HS and  
279 patient sub-groups are labeled on the X-axis and expressed as the relative OTU abundances  
280 per group.

281


**Figure 1****A****C****B****D****E**




Healthy subjects




IBD remission



IBD flare (no CDI)



IBD flare (CDI)



**Supplementary Table 1** : Lefse output : IBD without CDI vs IBD with CDI

OTU	Increased in	LDA	pvalue
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_New_ReferenceOTU12	no_ICD	2,709772134	0,042547194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU368950	no_ICD	2,126381739	0,042417294
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU523934	no_ICD	2,298329146	0,042612179
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU292228	no_ICD	2,334277874	0,042547194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU365574	no_ICD	2,395775029	0,042547194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU364109	no_ICD	2,464763391	0,042514711
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU346738	no_ICD	2,478248177	0,04264468
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU336133	no_ICD	2,652839773	0,013516916
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU370183	no_ICD	3,497785175	0,006901304
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales_OTU312882	no_ICD	2,138634014	0,029440095
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Coprococcus.s_OTU509416	no_ICD	2,764876219	0,009538398
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_OTU350091	no_ICD	2,222337607	0,042514711
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_OTU523542	no_ICD	2,354482673	0,029463885
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_OTU363232	no_ICD	2,506881192	0,029535294
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_OTU363064	no_ICD	3,048426578	0,034512032
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU333166	no_ICD	2,568375203	0,042547194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Mogibacteriaceae.g_.s_OTU197505	no_ICD	2,197417666	0,01343149
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Mogibacteriaceae.g_.s_OTU197329	no_ICD	2,229470457	0,042612179
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Mogibacteriaceae.g_.s_OTU591439	no_ICD	2,312112231	0,029630589
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Peptostreptococcaceae.g_.s_OTU547714	no_ICD	2,07927405	0,041764625
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU348406	no_ICD	2,351951641	0,0291788
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU330578	no_ICD	2,545676932	0,042482233
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU571642	no_ICD	2,548597635	0,042547194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU355307	no_ICD	2,593950091	0,042514711
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU363017	no_ICD	2,896417034	0,042612179
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU561607	no_ICD	2,963892372	0,042612179
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_.s_OTU1062061	no_ICD	3,13030404	0,020237338
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_New_ReferenceOTU26	ICD	3,159333048	0,020836678
k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.f_Bacteroidaceae.g_Bacteroides.s_uniformis_OTU197072	ICD	2,105371372	0,039902891
k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.f_Barnesiellaceae.g_.s_OTU3090117	ICD	2,280992361	0,014787029

k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_OTU3768338	ICD	2,035548356	0,007239643
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia.s_producta_OTU326865	ICD	2,289243933	0,033614828
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Blautia_362958	ICD	2,798873291	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_.s_306259	ICD	2,151239488	0,017782486
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_.s_OTU190003	ICD	2,153583951	0,024479083
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae_828483	ICD	3,047627085	0,005981652
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae_359750	ICD	3,44732167	0,000365284
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_.s_OTU606927	ICD	3,612199191	0,008833481
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_534957	ICD	2,017894414	0,022198769
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales_1846390	ICD	2,072160288	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales_New_CleanUp_ReferenceOTU22805	ICD	2,086165919	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_OTU198251	ICD	2,147435522	0,021612188
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_New_CleanUp_ReferenceOTU23027	ICD	2,176783737	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_OTU529180	ICD	2,25867102	0,027619597
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales_New_CleanUp_ReferenceOTU36592	ICD	2,344953413	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_OTU342397	ICD	2,865633643	0,0291519
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_g_.s_354798	ICD	3,27040575	0,00597103
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales_OTU628226	ICD	3,654128818	0,002459037
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_perfringens_650343	ICD	2,262257751	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_724298	ICD	2,488412305	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_perfringens_396697	ICD	2,780555912	0,000365284
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_butyricum_OTU541328	ICD	3,091233772	0,044571347
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_4352349	ICD	3,582042637	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Clostridiaceae.g_Clostridium.s_2670715	ICD	4,231520538	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Coprococcus.s_OTU300297	ICD	2,39102753	0,041918675
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Coprococcus.s_OTU259772	ICD	2,868751036	0,013633486
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_OTU196176	ICD	2,073798121	0,044719844
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Dorea.s_New_CleanUp_ReferenceOTU33563	ICD	2,236455645	0,014787029
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae_OTU225919	ICD	2,031815342	0,020070872
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae.g_Enterococcus.s_OTU777667	ICD	2,231527429	0,001438634
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae.g_Enterococcus.s_OTU810399	ICD	2,960440267	0,001510648
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae.g_Enterococcus.s_OTU1111582	ICD	3,316570625	0,041876848
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Epulopiscium.s_1658639	ICD	2,619604976	0,014787029
k_Bacteria.p_Firmicutes.c_Erysipelotrichi.o_Erysipelotrichales.f_Erysipelotrichaceae.g_.s_OTU262095	ICD	2,014896732	0,048335369

k_Bacteria.p_Firmicutes.c_Erysipelotrichi.o_Erysipelotrichales.f_Erysipelotrichaceae.g_.s_OTU356760	ICD	2,248239999	0,01665132
k_Bacteria.p_Firmicutes.c_Erysipelotrichi.o_Erysipelotrichales.f_Erysipelotrichaceae.g_.s_OTU360238	ICD	2,365767148	0,019426341
k_Bacteria.p_Proteobacteria.c_Gammaproteobacteria.o_Pasteurellales.f_Pasteurellaceae.g_Haemophilus.s_parainfluenzae_OTU160015	ICD	2,055478535	0,014015076
k_Bacteria.p_Proteobacteria.c_Gammaproteobacteria.o_Pasteurellales.f_Pasteurellaceae.g_Haemophilus.s_parainfluenzae_OTU1016422	ICD	2,175725828	0,01836869
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_New_CleanUp_ReferenceOTU29281	ICD	2,014500266	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_New_CleanUp_ReferenceOTU1777	ICD	2,033502038	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU186955	ICD	2,058689631	0,016187289
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU191999	ICD	2,10430887	0,013054349
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU2714942	ICD	2,112447997	0,020744402
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU4426877	ICD	2,144346253	0,028308724
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU515387	ICD	2,222776486	0,020529372
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU196990	ICD	2,278921856	0,012400722
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU186521	ICD	2,285395169	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU525142	ICD	2,307560565	0,022351007
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU554303	ICD	2,393225748	0,000249348
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU196370	ICD	2,961263016	0,013515946
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_New_CleanUp_ReferenceOTU41303	ICD	2,973537047	0,01460627
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_.s_OTU564806	ICD	3,059346739	0,009969624
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae_OTU198423	ICD	3,13442702	0,012613888
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_zeae_679245	ICD	2,219688181	0,014635653
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_794205	ICD	2,222146634	0,00240333
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_692823	ICD	2,275755931	0,020107819
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_OTU91147	ICD	2,372015581	0,016187289
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_New_ReferenceOTU28	ICD	2,565255835	0,008021195
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Lactobacillaceae.g_Lactobacillus.s_manihotivorans_OTU518033	ICD	2,649528161	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU2575651	ICD	2,057219895	0,033823367
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU183495	ICD	2,122071431	0,043954718
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU4338803	ICD	2,144541001	0,020486998
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU1551841	ICD	2,153436752	0,020738111
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_Ruminococcus.s_New_CleanUp_ReferenceOTU24360	ICD	2,233794941	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU1839271	ICD	2,250891702	0,011241596
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU416341	ICD	2,603989613	0,028308724
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Ruminococcus.s_gnavus_OTU360015	ICD	3,948864961	0,044232625
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Streptococcaceae.g_Streptococcus.s_4348151	ICD	2,011583756	0,002410416

k_Bacteria.p_Proteobacteria.c_Betaproteobacteria.o_Burkholderiales.f_Alcaligenaceae.g_Sutterella.s_OTU215097	ICD	2,913196942	0,014787029
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Epulopiscium.s_2575786	ICD	2,504195664	0,00240333
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Epulopiscium.s_295029	ICD	3,028901583	0,014635653
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Epulopiscium.s_298247	ICD	3,26744118	0,013164598

**Table 1 :** Characteristics of patients

	IBD flare CDI (n=8)		IBD flare (n=24)		IBD remission (n=24)		HS (n=24)
Age : Year (mean +/- SD)	33.4 +/- 10.5		36.5 +/- 11.6		36.5 +/- 11.6		33.0 +/- 10.2
Male : n (%)	5 (62.6%)		14 (58.3%)		14 (58.3%)		15 (62.5%)
Active smoking : n(%)	2 (25.0%)		9 (37.5%)		9 (37.5%)		1 (4.2%)
CD/UC : n(%)	CD	UC	CD	UC	CD	UC	NA
n (%)	6 (75%)	2 (25%)	18 (75%)	6 (25%)	18 (75%)	6 (25%)	NA
<b>Montreal classification</b>							
A1 / A2 / A3 (n)	6 / 0 / 0	NA	4 / 12 / 2	NA	3 / 15 / 0	NA	NA
L1 / L2 / L3 (n)	2 / 2 / 2	NA	6 / 6 / 6	NA	6 / 6 / 6	NA	NA
B1 / B2 / B3 (n)	4 / 0 / 2	NA	9 / 2 / 7	NA	6 / 2 / 10	NA	NA
E1 / E2 / E3 (n)	NA	0 / 1 / 1	NA	0 / 3 / 3	NA	0 / 3 / 3	NA
<b>Treatment: n(%)</b>							NA
5-ASA	3 (37.5%)		10 (41.7%)		6 (25.9%)		0
Corticosteroids	1 (12.5%)		10 (41.7%)		1 (4.2%)		0
Thiopurine or MTX	1 (12.5%)		10 (41.7%)		10 (41.7%)		0
anti-TNF $\alpha$	2 (25.0%)		13 (54.2%)		19 (79.2%)		0
Antibiotics	0		0		0		0